Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
SGK1 inhibitor is an ATP-competitive inhibitor of serum/glucocorticoid-regulated kinase 1 (SGK1) and SGK2 (IC50s = 0.442 and 0.924 µM, respectively).1 It is selective for SGK1 and SGK2 over SGK3 (IC50 = 23.3 μM) and a panel of 60 additional kinases at 1 μM but does inhibit AMP-activated protein kinase (AMPK) by greater than 50% at 1 µM.2 SGK1 inhibitor (5 µM) reduces ERK phosphorylation and inhibits colony formation in AML12 hepatocytes expressing DNAJ-PKAc, a fusion protein found in fibrolamellar carcinoma tumors.3 It also reduces phosphorylation of glycogen synthase kinase 3β (GSK3β) in U2OS cells (IC50 = 1.4 μM) and sensitizes HCC1954 hepatocellular carcinoma cells to the PI3Kα inhibitor BYL719 (Item No. 16986).2,1 SGK1 inhibitor (50 mg/kg) enhances the reduction in tumor growth induced by BYL719 in an HCC1954 mouse xenograft model.
WARNING This product is not for human or veterinary use.
1. PDK1-
2. Discovery of N-
3. Distinct phases of cellular signaling revealed by time-